Disc Medicine (IRON) Cash from Financing Activities (2020 - 2026)

Disc Medicine (IRON) has 7 years of Cash from Financing Activities data on file, last reported at $1.7 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $1.7 million, down 99.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $230.9 million (down 48.32% YoY), and the FY2025 annual result was $473.4 million, up 116.85% from the prior year.
• Cash from Financing Activities slipped to $1.7 million in Q1 2026 per IRON's latest filing, from $216.7 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $244.3 million in Q1 2025 and troughed at $22000.0 in Q3 2022.
• A 5-year average of $63.6 million and a median of $11.6 million in 2025 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities slumped 99.97% in 2022, then jumped 178801.16% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $148.8 million in 2022, then slumped by 94.79% to $7.8 million in 2023, then jumped by 271.19% to $28.8 million in 2024, then soared by 652.43% to $216.7 million in 2025, then slumped by 99.22% to $1.7 million in 2026.
• Business Quant data shows IRON's Cash from Financing Activities at $1.7 million in Q1 2026, $216.7 million in Q4 2025, and $11.6 million in Q3 2025.